Clinical Trial

Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025

Study acronym: DREPIBAC
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Children with sickle cell disease are at high risk of invasive bacterial infections, which may lead to serious complications. Preventive measures, including antibiotic prophylaxis and vaccination, have changed the epidemiology of these infections over time. New pneumococcal conjugate vaccines have recently become available, and updated data are needed to better understand which bacteria are currently responsible for invasive infections in this population. The aim of this retrospective study is to describe the bacterial distribution of invasive bacterial infections in children with sickle cell disease in France between 2020 and 2025. The results may help improve knowledge of these infections and guide future prevention strategies, including antibiotic management and vaccination policies.
Trial Details
NCT Number NCT07639008
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Sickle Cell Disease (SCD), Invasive Bacterial Infections
Enrollment 350 participants
Start Date 2026-07-15
Primary Completion 2027-07-15 (estimated)
Study Completion 2027-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-10